The Effect of Corynanthine on Intraocular Pressure in Clinical Trials
A single drop, dose-response, double-masked study of the effect of corynanthine, a selective α1 adrenergic antagonist, on intraocular pressure (IOP) was carried out in 10 symmetrically ocular hypertensive patients. Corynanthine 1 % had no significant pressure lowering effect. Topical application of...
Gespeichert in:
| Veröffentlicht in: | Ophthalmology (Rochester, MN) MN), 1985-07, Vol.92 (7), p.977-980 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 980 |
|---|---|
| container_issue | 7 |
| container_start_page | 977 |
| container_title | Ophthalmology (Rochester, MN) |
| container_volume | 92 |
| creator | Serle, Janet B. Podos, Steven M. Lustgarten, Jacqueline S. Teitelbaum, Charles Severin, Colette H. |
| description | A single drop, dose-response, double-masked study of the effect of corynanthine, a selective α1 adrenergic antagonist, on intraocular pressure (IOP) was carried out in 10 symmetrically ocular hypertensive patients. Corynanthine 1 % had no significant pressure lowering effect. Topical application of a 2% solution significantly (P < 0.05) reduced IOP for at least eight hours; at five hours; mean IOP (±SEM) was 20.6 ± 2.0 mmHg and 26.0 ± 4.9 mmHg, comparing treated and control eyes, respectively. The 5% solution caused a significant (P ± 0.05) bilateral reduction in IOP, comparing treated and control eyes to baseline IOP respectively. Two percent corynanthine applied topically two or three times daily for one, two, or three weeks to seven patients with symmetrical ocular hypertension did not reduce IOP. Alpha adrenergic antagonists may have a role in the treatment of glaucoma. |
| doi_str_mv | 10.1016/S0161-6420(85)33950-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76233075</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0161642085339507</els_id><sourcerecordid>76233075</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-92d3caf7fe2c50f78ad040bbd223cb63c23150cfb020a417adabd82705f7231d3</originalsourceid><addsrcrecordid>eNqFkE1rGzEQhkVJcR23PyGgQwnNYdORtJJ2TyEYJzEYWqh7Flp9EJW1NpF2A_73VWzjay6aw_vMaOZB6IrALQEifv4pD6lETeFHw28YazlU8hOaE163VS0Ju0DzM_IFXeb8DwCEYPUMzWgjqCDtHK22zw6vvHdmxIPHyyHto47jc4gODxGv45j0YKZeJ_w7uZyn5HCIeNmHGIzu8TYF3eev6LMvxX071QX6-7DaLp-qza_H9fJ-UxnWtGPVUsuM9tI7ajh42WgLNXSdpZSZTjBDGeFgfAcUdE2ktrqzDZXAvSyRZQt0fZz7kobXyeVR7UI2ru91dMOUlRSUMZC8gPwImjTknJxXLynsdNorAupdnzroU-9uVMPVQZ-Spe_q9MHU7Zw9d518lfz7Kde5nO-TjibkM9bShoGoC3Z3xFyR8RZcUtkEF42zIRXTyg7hg0X-A0_Li1U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76233075</pqid></control><display><type>article</type><title>The Effect of Corynanthine on Intraocular Pressure in Clinical Trials</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Serle, Janet B. ; Podos, Steven M. ; Lustgarten, Jacqueline S. ; Teitelbaum, Charles ; Severin, Colette H.</creator><creatorcontrib>Serle, Janet B. ; Podos, Steven M. ; Lustgarten, Jacqueline S. ; Teitelbaum, Charles ; Severin, Colette H.</creatorcontrib><description>A single drop, dose-response, double-masked study of the effect of corynanthine, a selective α1 adrenergic antagonist, on intraocular pressure (IOP) was carried out in 10 symmetrically ocular hypertensive patients. Corynanthine 1 % had no significant pressure lowering effect. Topical application of a 2% solution significantly (P < 0.05) reduced IOP for at least eight hours; at five hours; mean IOP (±SEM) was 20.6 ± 2.0 mmHg and 26.0 ± 4.9 mmHg, comparing treated and control eyes, respectively. The 5% solution caused a significant (P ± 0.05) bilateral reduction in IOP, comparing treated and control eyes to baseline IOP respectively. Two percent corynanthine applied topically two or three times daily for one, two, or three weeks to seven patients with symmetrical ocular hypertension did not reduce IOP. Alpha adrenergic antagonists may have a role in the treatment of glaucoma.</description><identifier>ISSN: 0161-6420</identifier><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/S0161-6420(85)33950-7</identifier><identifier>PMID: 2862619</identifier><identifier>CODEN: OPHTDG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adrenergic alpha-Antagonists - therapeutic use ; Adult ; Aged ; alpha adrenergic antagonist ; Biological and medical sciences ; Blood Pressure - drug effects ; Clinical Trials as Topic ; corynanthine ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Eye ; Female ; Humans ; intraocular pressure ; Intraocular Pressure - drug effects ; Male ; Medical sciences ; Middle Aged ; ocular hypertension ; Ocular Hypertension - drug therapy ; Ophthalmic Solutions ; Pharmacology. Drug treatments ; Yohimbine - therapeutic use</subject><ispartof>Ophthalmology (Rochester, MN), 1985-07, Vol.92 (7), p.977-980</ispartof><rights>1985 American Academy of Opthalmology, Inc.</rights><rights>1985 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-92d3caf7fe2c50f78ad040bbd223cb63c23150cfb020a417adabd82705f7231d3</citedby><cites>FETCH-LOGICAL-c389t-92d3caf7fe2c50f78ad040bbd223cb63c23150cfb020a417adabd82705f7231d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0161-6420(85)33950-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9283064$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2862619$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Serle, Janet B.</creatorcontrib><creatorcontrib>Podos, Steven M.</creatorcontrib><creatorcontrib>Lustgarten, Jacqueline S.</creatorcontrib><creatorcontrib>Teitelbaum, Charles</creatorcontrib><creatorcontrib>Severin, Colette H.</creatorcontrib><title>The Effect of Corynanthine on Intraocular Pressure in Clinical Trials</title><title>Ophthalmology (Rochester, MN)</title><addtitle>Ophthalmology</addtitle><description>A single drop, dose-response, double-masked study of the effect of corynanthine, a selective α1 adrenergic antagonist, on intraocular pressure (IOP) was carried out in 10 symmetrically ocular hypertensive patients. Corynanthine 1 % had no significant pressure lowering effect. Topical application of a 2% solution significantly (P < 0.05) reduced IOP for at least eight hours; at five hours; mean IOP (±SEM) was 20.6 ± 2.0 mmHg and 26.0 ± 4.9 mmHg, comparing treated and control eyes, respectively. The 5% solution caused a significant (P ± 0.05) bilateral reduction in IOP, comparing treated and control eyes to baseline IOP respectively. Two percent corynanthine applied topically two or three times daily for one, two, or three weeks to seven patients with symmetrical ocular hypertension did not reduce IOP. Alpha adrenergic antagonists may have a role in the treatment of glaucoma.</description><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>alpha adrenergic antagonist</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Clinical Trials as Topic</subject><subject>corynanthine</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Eye</subject><subject>Female</subject><subject>Humans</subject><subject>intraocular pressure</subject><subject>Intraocular Pressure - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>ocular hypertension</subject><subject>Ocular Hypertension - drug therapy</subject><subject>Ophthalmic Solutions</subject><subject>Pharmacology. Drug treatments</subject><subject>Yohimbine - therapeutic use</subject><issn>0161-6420</issn><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1rGzEQhkVJcR23PyGgQwnNYdORtJJ2TyEYJzEYWqh7Flp9EJW1NpF2A_73VWzjay6aw_vMaOZB6IrALQEifv4pD6lETeFHw28YazlU8hOaE163VS0Ju0DzM_IFXeb8DwCEYPUMzWgjqCDtHK22zw6vvHdmxIPHyyHto47jc4gODxGv45j0YKZeJ_w7uZyn5HCIeNmHGIzu8TYF3eev6LMvxX071QX6-7DaLp-qza_H9fJ-UxnWtGPVUsuM9tI7ajh42WgLNXSdpZSZTjBDGeFgfAcUdE2ktrqzDZXAvSyRZQt0fZz7kobXyeVR7UI2ru91dMOUlRSUMZC8gPwImjTknJxXLynsdNorAupdnzroU-9uVMPVQZ-Spe_q9MHU7Zw9d518lfz7Kde5nO-TjibkM9bShoGoC3Z3xFyR8RZcUtkEF42zIRXTyg7hg0X-A0_Li1U</recordid><startdate>198507</startdate><enddate>198507</enddate><creator>Serle, Janet B.</creator><creator>Podos, Steven M.</creator><creator>Lustgarten, Jacqueline S.</creator><creator>Teitelbaum, Charles</creator><creator>Severin, Colette H.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198507</creationdate><title>The Effect of Corynanthine on Intraocular Pressure in Clinical Trials</title><author>Serle, Janet B. ; Podos, Steven M. ; Lustgarten, Jacqueline S. ; Teitelbaum, Charles ; Severin, Colette H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-92d3caf7fe2c50f78ad040bbd223cb63c23150cfb020a417adabd82705f7231d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>alpha adrenergic antagonist</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Clinical Trials as Topic</topic><topic>corynanthine</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Eye</topic><topic>Female</topic><topic>Humans</topic><topic>intraocular pressure</topic><topic>Intraocular Pressure - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>ocular hypertension</topic><topic>Ocular Hypertension - drug therapy</topic><topic>Ophthalmic Solutions</topic><topic>Pharmacology. Drug treatments</topic><topic>Yohimbine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Serle, Janet B.</creatorcontrib><creatorcontrib>Podos, Steven M.</creatorcontrib><creatorcontrib>Lustgarten, Jacqueline S.</creatorcontrib><creatorcontrib>Teitelbaum, Charles</creatorcontrib><creatorcontrib>Severin, Colette H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, MN)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Serle, Janet B.</au><au>Podos, Steven M.</au><au>Lustgarten, Jacqueline S.</au><au>Teitelbaum, Charles</au><au>Severin, Colette H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effect of Corynanthine on Intraocular Pressure in Clinical Trials</atitle><jtitle>Ophthalmology (Rochester, MN)</jtitle><addtitle>Ophthalmology</addtitle><date>1985-07</date><risdate>1985</risdate><volume>92</volume><issue>7</issue><spage>977</spage><epage>980</epage><pages>977-980</pages><issn>0161-6420</issn><eissn>1549-4713</eissn><coden>OPHTDG</coden><abstract>A single drop, dose-response, double-masked study of the effect of corynanthine, a selective α1 adrenergic antagonist, on intraocular pressure (IOP) was carried out in 10 symmetrically ocular hypertensive patients. Corynanthine 1 % had no significant pressure lowering effect. Topical application of a 2% solution significantly (P < 0.05) reduced IOP for at least eight hours; at five hours; mean IOP (±SEM) was 20.6 ± 2.0 mmHg and 26.0 ± 4.9 mmHg, comparing treated and control eyes, respectively. The 5% solution caused a significant (P ± 0.05) bilateral reduction in IOP, comparing treated and control eyes to baseline IOP respectively. Two percent corynanthine applied topically two or three times daily for one, two, or three weeks to seven patients with symmetrical ocular hypertension did not reduce IOP. Alpha adrenergic antagonists may have a role in the treatment of glaucoma.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>2862619</pmid><doi>10.1016/S0161-6420(85)33950-7</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-6420 |
| ispartof | Ophthalmology (Rochester, MN), 1985-07, Vol.92 (7), p.977-980 |
| issn | 0161-6420 1549-4713 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76233075 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adrenergic alpha-Antagonists - therapeutic use Adult Aged alpha adrenergic antagonist Biological and medical sciences Blood Pressure - drug effects Clinical Trials as Topic corynanthine Dose-Response Relationship, Drug Drug Administration Schedule Eye Female Humans intraocular pressure Intraocular Pressure - drug effects Male Medical sciences Middle Aged ocular hypertension Ocular Hypertension - drug therapy Ophthalmic Solutions Pharmacology. Drug treatments Yohimbine - therapeutic use |
| title | The Effect of Corynanthine on Intraocular Pressure in Clinical Trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T20%3A03%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effect%20of%20Corynanthine%20on%20Intraocular%20Pressure%20in%20Clinical%20Trials&rft.jtitle=Ophthalmology%20(Rochester,%20MN)&rft.au=Serle,%20Janet%20B.&rft.date=1985-07&rft.volume=92&rft.issue=7&rft.spage=977&rft.epage=980&rft.pages=977-980&rft.issn=0161-6420&rft.eissn=1549-4713&rft.coden=OPHTDG&rft_id=info:doi/10.1016/S0161-6420(85)33950-7&rft_dat=%3Cproquest_cross%3E76233075%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76233075&rft_id=info:pmid/2862619&rft_els_id=S0161642085339507&rfr_iscdi=true |